The approval was based on data from 3 phase 3 trials which compared the efficacy of different dosing regimens of ...

Targeted prevention strategies and increased public awareness and vaccination coverage are needed to reduce the significant ...

After grave missteps in the COVID-19 pandemic, the World Health Organization revisited the science and now confirms that many respiratory viruses are inhaled as airborne particles. The new framework ...

Credit: Getty Images Diagnosing patients with neurologic Lyme disease can take upwards of 2 years, which Maria Arini Lopez discovered first-hand in the spring of 2021. Lyme Disease Awareness Month ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Patients with advanced cancer receiving outpatient palliative care preferred telehealth over in-person visits even after the COVID-19 pandemic ended. Even after the SARS-CoV-2 vaccine against COVID-19 ...

Pregnant patients should discontinue use of thiopurines if they develop intrahepatic cholestasis of pregnancy. The use of thiopurines (eg, azathioprine, 6-mercaptopurine, and 6-thioguanine) by ...

SARS-CoV-2 antibody levels may be a correlate for immunity against COVID-19 infection and help determine the optimal timing of booster receipt. Serologic testing may allow individual-level assessment ...

Rubbing your eyes might feel satisfying but it could introduce pathogens to the body. Here’s a summary of the most common eye infections. The Conversation — When you think of eye infections, what ...

More rapid and targeted microbial treatment for patients with community-acquired pneumonia occurred via routine use of polymerase chain reaction testing for lower respiratory tract pathogens.

Findings suggest the need to reconsider American Society of Anesthesiologists 2023 guidelines recommending that glucagon-like peptide 1 receptor agonists be withheld from patients preoperatively.

A regulatory decision is expected in the fourth quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for tapinarof cream, 1% for the ...